PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|July 2, 2008
- Pharmaceutical Technology-07-02-2008
- Volume 32
- Issue 7
Trends: Industry Job Cuts
Author(s)Angie Drakulich
Staff reductions are not surprising with the state of the economy and falling pharmaceutical sales.
Advertisement
Given the current state of the economy and the fact that pharmaceutical sales have been crunched over the past several years, job cuts are not surprising. The US unemployment rate has gone up a full percentage point in the past year, from 4.5% in May 2007 to 5.5% in May 2008; the rate in New Jersey went up from 4.3% to 5.0%. Below is a look at some of the largest cuts that pharmaceutical companies—nearly half of them based in New Jersey—have announced since early 2007.
(Raymond Medici/Getty Images, Cartesia/Getty Images)
Companies and announced job cuts
Articles in this issue
about 18 years ago
Coming Down the Pike: Protein-Substrate Bindingabout 18 years ago
Self-Emulsifying Drug Delivery Systemsabout 18 years ago
A Path to Quality and Complianceabout 18 years ago
Excipients in Polymeric Drug Delivery and Formulationsabout 18 years ago
ePedigree: Using the Gift of Time Wiselyabout 18 years ago
Variables Affecting Reconstitution Time of Dry Powder for Injectionabout 18 years ago
Report From: The Netherlandsabout 18 years ago
Manufacturing Insights: Pfizerabout 18 years ago
Inside IPEC: Dual-Use LabelingAdvertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement